SBIR/STTR Research Award
Innovation Corps supporting BoostOne SBIR
Award amount
$300,648Program and phase
SBIR · Phase IAward year
2021Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- NXTECH INC
- Proposal award date
- 2021-07-15
- Contract end date
- 2023-03-31
- UEI
- XLK6RTZF2MG4
- Solicitation number
- PAR22-073
- Topic code
- NIDA
Research abstract
Project Summary
Individuals with opioid use disorder (OUD) face both short-term and long-term challenges to
healthy and productive decision-making. While recovery success is deeply affected by
phasic/psychological propensity for re-use, current strategies for cravings control suffer from
limited usability and restricted utility. The proposed innovation (“BoostONE”) comprises a
proprietary software-delivered method for just-in-time management of such risk events, as a
supplement to standard medication assisted treatment for OUD. Aims include platform
refinement and a real-world feasibility study. We anticipate this Phase I SBIR will provide the
foundation for deployment of BoostONE in active treatment settings and for broader extensions
of the underlying novel technology framework.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- BoostPrime, A Novel Digital Therapeutic for Craving Mitigation in OUD
- BoostPrime, A Novel Digital Therapeutic for Craving Mitigation in OUD
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Wearable Wireless Respiratory Monitoring System that Detects and Predicts Opioid Induced Respiratory Depression
- Building and testing the Life Enhancement and Advocacy Programming digital training tool (LEAPLink) to better serve people with lived experience of homelessness and substance use disorder
- A digital intervention to decrease self-stigma among pregnant and postpartum women with opioid use disorder
- Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.
- Creation and Validation of the Dose-Opioid-Source Evaluation tool (DOSE) - a Robust Opioid Use Clinical Outcome Assessment for Qualification as an FDA Medical Device Development Tool (MDDT)
Research funding history
3 SBIR/STTR records share this UEI (2021–2025). Reported award amounts total $1,776,772. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services